NCT07166081View on ClinicalTrials.gov

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects

PHASE1RecruitingINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

January 12, 2026

Study Completion Date

May 13, 2026

Conditions

Non-diabetic Overweight or Obese

Interventions

DRUG

BGM0504

Administered orally

DRUG

BGM0504

Administered orally

DRUG

BGM0504

Administered orally

DRUG

Placebo

Administered orally

DRUG

BGM0504

Administered orally

Trial Locations (1)

21201

RECRUITING

Pharmaron CPC, Inc, Baltimore

All Listed Sponsors

lead

BrightGene Bio-Medical Technology Co., Ltd.

INDUSTRY